[1]	World Alzheimer Report 2018[R/OL]. (2018-12-19)[2018-04-15].https://www.alzsint.org/resource/world-alzheimer-report-2018/ https://www.alzsint.org/resource/world-alzheimer-report-2018/ Cited in this article [1]

[2]	Jia L, Du Y, Chu L, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study[J]. Lancet Public Health, 2020, 5(12):e661-e671. Cited in this article [1]

[3]	Wang X, Wang C, Pei G, et al. α-secretase ADAM10 physically interacts with β-secretase BACE1 in neurons and regulates CHL1 proteolysis[J]. J Mol Cell Biol, 2018, 10(5):411-422. Cited in this article [2]

[4]	Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics[J]. Science, 2002, 297(5580):353-356. Cited in this article [3]

[5]	Bonda DJ, Lee HG, Camins A, et al. The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations[J]. Lancet Neurol, 2011, 10(3):275-279. Cited in this article [1]

[6]	Tracy TE, Madero-Pérez J, Swaney DL, et al. Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration[J]. Cell, 2022, 185(4):712-728.e14. Cited in this article [1]

[7]	García-Sierra F, Mondragón-Rodríguez S, Basurto-Islas G, et al. Truncation of tau protein and its pathological significance in Alzheimer's disease[J]. J Alzheimers Dis, 2008, 14(4):401-409. Cited in this article [1]

[8]	Zhang Z, Zhao R, Qi J, et al. Inhibition of glycogen synthase kinase-3β by Angelica sinensis extract decreases β-amyloid-induced neurotoxicity and tau phosphorylation in cultured cortical neurons[J]. J Neurosci Res, 2011, 89(3):437-447. Cited in this article [1]

[9]	Chao WW, Hong YH, Chen ML, et al. Inhibitory effects of angelica sinensis ethyl acetate extract and major compounds on NF-kappaB trans-activation activity and LPS-induced inflammation[J]. J Ethnopharmacol, 2010, 129(2):244-249. Cited in this article [2]

[10]	Johansson S, Jämsä A, Vasänge M, et al. Increased tau phosphorylation at the Ser396 epitope after amyloid beta-exposure in organotypic cultures[J]. Neuroreport, 2006, 17(9):907-911. Cited in this article [2]

[11]	Elyaman W, Terro F, Wong NS, et al. In vivo activation and nuclear translocation of phosphorylated glycogen synthase kinase-3beta in neuronal apoptosis: links to tau phosphorylation[J]. Eur J Neurosci, 2002, 15(4):651-660. Cited in this article [1]

[12]	Husain MA, Laurent B, Plourde M, et al. APOE and Alzheimer's disease: from lipid transport to physiopathology and therapeutics[J]. Front Neurosci, 2021, 15:630502. Cited in this article [1]

[13]	Norwitz NG, Saif N, Ariza IE, et al. Precision nutrition for Alzheimer's prevention in ApoE4 carriers[J]. Nutrients, 2021, 13(4):1362. Cited in this article [1]

[14]	Alzheimer's Association. Is Alzheimer's Genetic?[EB/OL]. (2021-12-19)[2021-04-15].https://www.alz.org/alzheimers-dementia/what-is-alzheimers/causes-and-risk-factors/genetics. https://www.alz.org/alzheimers-dementia/what-is-alzheimers/causes-and-risk-factors/genetics Cited in this article [1]

[15]	Michaelson DM. APOE ε4: the most prevalent yet understudied risk factor for Alzheimer's disease[J]. Alzheimers Dement, 2014, 10(6):861-868. Cited in this article [1]

[17]	Wang YY, Ge YJ, Tan CC, et al. The proportion of APOE4 carriers among non-demented individuals: a pooled analysis of 389,000 community-dwellers[J]. J Alzheimers Dis, 2021, 81(3):1331-1339. Cited in this article [2]

[18]	Doucette R, Fisman M, Hachinski VC, et al. Cell loss from the nucleus basalis of Meynert in Alzheimer's disease[J]. Can J Neurol Sci, 1986, 13(4 Suppl):435-440. Cited in this article [1]

[19]	Sochocka M, Zwolińska K, Leszek J, et al. The infectious etiology of Alzheimer's disease[J]. Curr Neuropharmacol, 2017, 15(7):996-1009. Cited in this article [1]

[20]	Abbott A. Are infections seeding some cases of Alzheimer's disease?[J]. Nature, 2020, 587(7832):22-25.

[21]	Lin WR, Wozniak MA, Cooper RJ, et al. Herpesviruses in brain and Alzheimer's disease[J]. J Pathol, 2002, 197(3):395-402. Cited in this article [1]

[22]	Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease[J]. Neurobiol Aging, 2000, 21(3):383-421. Cited in this article [1]

[23]	Soscia SJ, Kirby JE, Washicosky KJ, et al. The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide[J]. PLoS One, 2010, 5(3):e9505. Cited in this article [2]

[24]	McGeer PL, Rogers J, McGeer EG, et al. Inflammation, Antiinflammatory agents, and Alzheimer's disease: the last 22 years[J]. J Alzheimers Dis, 2016, 54(3):853-857. Cited in this article [1]

[25]	Itzhaki RF. Corroboration of a major role for herpes simplex virus type 1 in Alzheimer's disease[J]. Front Aging Neurosci, 2018, 10:324. Cited in this article [1]

[26]	Huang J, Su B, Karhunen V, et al. Inflammatory diseases, inflammatory biomarkers, and Alzheimer disease: an observational analysis and mendelian randomization[J]. Neurology, 2023, 100(6):e568-e581. Cited in this article [1]

[27]	Adlard PA, Bush AI. Metals and Alzheimer's disease: how far have we come in the clinic?[J]. J Alzheimers Dis, 2018, 62(3):1369-1379. Cited in this article [1]

[28]	Levi S, Finazzi D. Neurodegeneration with brain iron accumulation: update on pathogenic mechanisms[J]. Front Pharmacol, 2014, 5:99. Cited in this article [1]

[29]	Olesen RH, Hyde TM, Kleinman JE, et al. Obesity and age-related alterations in the gene expression of zinc-transporter proteins in the human brain[J]. Transl Psychiatry, 2016, 6(6):e838. Cited in this article [1]

[30]	Hansson O, Zetterberg H, Vanmechelen E, et al. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment[J]. Neurobiol Aging, 2010, 31(3):357-367. Cited in this article [1]

[31]	Janelidze S, Stomrud E, Palmqvist S, et al. Plasma beta-amyloid in Alzheimer's disease and vascular disease[J]. Sci Rep, 2016, 6:26801. Cited in this article [1]

[32]	Palmqvist S, Janelidze S, Stomrud E, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status[J]. JAMA Neurol, 2019, 76(10):1060-1069. Cited in this article [1]

[33]	Pannee J, Tornqvist U, Westerlund A, et al. The amyloid-beta degradation pattern in plasma-a possible tool for clinical trials in Alzheimer's disease[J]. Neurosci Lett, 2014, 573:7-12. Cited in this article [1]

[34]	Schmidt SD, Nixon RA, Mathews PM, et al. ELISA method for measurement of amyloid-beta levels[J]. Methods Mol Biol, 2005, 299:279-297. Cited in this article [1]

[35]	Brenes A, Hukelmann J, Bensaddek D. et al. Multibatch TMT reveals false positives, batch effects and missing values[J]. Mol Cell Proteomics, 2019, 18(10):1967-1980. Cited in this article [1]

[36]	Gold L, Ayers D, Bertino J, et al. Aptamer-based multiplexed proteomic technology for biomarker discovery[J]. PLoS One, 2010, 5(12):e15004. Cited in this article [1]

[37]	Rissin DM, Fournier DR, Piech T, et al. Simultaneous detection of single molecules and singulated ensembles of molecules enables immunoassays with broad dynamic range[J]. Anal Chem, 2011, 83(6):2279-2285. Cited in this article [1]

[38]	Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis[J]. Lancet Neurol, 2016, 15(7):673-684. Cited in this article [1]

[39]	Rissin DM, Kan CW, Campbell TG, et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations[J]. Nat Biotechnol, 2010, 28(6):595-599. Cited in this article [1]

[40]	Rissin DM, Fournier DR, Piech T, et al. Simultaneous detection of single molecules and singulated ensembles of molecules enables immunoassays with broad dynamic range[J]. Anal Chem, 2011, 83(6):2279-2285. Cited in this article [1]

[41]	De Meyer S, Schaeverbeke JM, Verberk IMW, et al. Comparison of ELISA- and SIMOA-based quantification of plasma Abeta ratios for early detection of cerebral amyloidosis[J]. Alzheimers Res Ther, 2020, 12(1):162. Cited in this article [1]

[42]	Pais MV, Forlenza OV, Diniz BS, et al. Plasma biomarkers of Alzheimer's disease: a review of available assays, recent developments, and implications for clinical practice[J]. J Alzheimers Dis Rep, 2023, 7(1):355-380. Cited in this article [3]

[43]	Khalafi M, Dartora WJ, McIntire LBJ, et al. Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer's disease pathology among cognitively impaired and unimpaired: a systematic review and meta-analysis[J]. Alzheimers Dement, 2024, 1-21. Cited in this article [1]

[44]	Xiao Z, Wu W, Ma X, et al. Plasma p-tau217, p-tau181, and NfL as early indicators of dementia risk in a community cohort: The Shanghai Aging Study[J]. Alzheimers Dement, 2023, 15:e12514. Cited in this article [1]

[45]	Janelidze S, Teunissen CE, Zetterberg H, et al. Head-to-head comparison of 8 plasma amyloid-beta 42/40 assays in Alzheimer disease[J]. JAMA Neurol, 2021, 78(11):1375-1382. Cited in this article [1]